Laurus Labs

Hyderabad, India
Small Molecule API Finished Dosage Form (FDF) CDMO (small molecule) Biologics / Large Molecule Microbial Fermentation Peptide API Cell & Gene Therapy (early-stage investment) Anti-retroviral API Oncology API ADC (emerging)
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ✓ Press (10) ○ EMA GMP ○ MHRA GMP

Quick Facts: Laurus Labs

Signal Score
60.0/100
Quality Compliance
Assessment pending
Headquarters
Hyderabad, India
Modalities
Small Molecule API, Finished Dosage Form (FDF), CDMO (small molecule), Biologics / Large Molecule, Microbial Fermentation, Peptide API, Cell & Gene Therapy (early-stage investment), Anti-retroviral API, Oncology API, ADC (emerging)
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Laurus Labs

Auto-created by AI matchmaker. Data verification pending.

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesSmall Molecule API, Finished Dosage Form (FDF), CDMO (small molecule), Biologics / Large Molecule, Microbial Fermentation, Peptide API, Cell & Gene Therapy (early-stage investment), Anti-retroviral API, Oncology API, ADC (emerging)
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 60.0
Broad modality coverage (10 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press10 articles
Broad modality coverage (10 modalities)

Recent News 10 articles

news Thu, 07 Ma
Laurus Labs Accelerates Transformation on Strong CDMO Execution - Moneylife
Source →
news Sun, 18 Ja
Why market is betting big on Laurus Labs even at 85x P/E - Value Research
Source →
news Mon, 18 Ma
CDMO stocks in focus: Laurus Labs hits new high; Sai Life Sciences gains 2% - Business Standard
Source →
news Mon, 08 De
Laurus Labs Strengthens CDMO Focus After Strong ARV Foundation - The Indian Practitioner
Source →
news Mon, 05 Ja
Laurus Labs, Biocon, Rubicon Lead Motilal Oswal’s Top Picks As Q3 Healthcare Outlook Brightens — Check Details - NDTV Profit
Source →
news Mon, 04 Ma
Laurus Labs bets on CDMO scale-up, sees strong margin expansion ahead - CNBC TV18
Source →
news Fri, 26 Ju
Brokerages stay bullish on Laurus Labs as CDMO momentum and margins improve - The Economic Times
Source →
news Fri, 23 Ja
Laurus Labs Q3 PAT jumps 173% on strong generics, CDMO momentum - Moneycontrol.com
Source →
news Fri, 05 De
Laurus Labs betting big on CDMO segment to power future growth - The Times of India
Source →
news Fri, 01 Ma
Laurus Labs FY26 revenue rises 23% to Rs 6,813 Crore; EBITDA surges 64% - Indian Pharma Post
Source →

Frequently Asked Questions About Laurus Labs

What is Laurus Labs's CDMO Signal Score?
Laurus Labs has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Laurus Labs for a manufacturing program?
Use the free AI matchmaker to compare Laurus Labs against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Biologics / Large Molecule CDMOs → ADC (emerging) CDMOs →

Similar CDMOs

Olon Group
Rodano (Milan), Italy
Small Molecule API, HPAPI / Cytotoxics, Microbial Fermentation, Mammalian Cell Culture, Recombinant Proteins / Enzymes, Biologics (mAbs), ADC (end-to-end bioconjugation), Oligonucleotide / Peptide, Chemical Synthesis, Semi-Synthesis
Sun Pharmaceutical Industries Ltd.
Mumbai, India
Small Molecule API, Oral Solid Dose, Sterile Injectables, Specialty Generics, Novel Chemical Entities (NCE) via CRAMS, Biologics (via CMO partnerships), Specialty/Innovative Medicines
Sai Life Sciences
Hyderabad, India
Small Molecule API, Complex Small Molecules, HPAPI, ADC, Peptides, Oligonucleotides, Lipids / LNP, Intermediates, Drug Discovery (CRO)
Torrent Pharmaceuticals Limited
Ahmedabad, India
Small Molecule API, Oral Solid Dose, Sterile Injectables, Generic Drug Products, CDMO (via JB Pharma acquisition)
Aarti Pharmalabs Limited
Mumbai, India
Small Molecule API, Steroid / Corticosteroid API, HPAPI, Anti-cancer / Cytotoxic API, Xanthine Derivatives, NCE Drug Substance